Free webinar at 1:00 p.m. Eastern time (US), April 15, 2026

Sustained potential (SP) is a neural response to periodic auditory stimuli registered with EEG 40Hz Auditory Steady-State Response. The talk addresses the potential to define different language subgroups in autism and to use this biomarker in clinical trials.

Sustained Potential as a Biomarker of Language Functioning in Autism

This field is for validation purposes and should be left unchanged.
Name(Required)



About the speaker:

Dr. Vardan Arutiunian, PhD, is currently a postdoctoral fellow at Azrieli Research Center in Sainte-Justine Mother and Child University Hospital Center (CHU Sainte-Justine), University of Montreal in Sarah Lippe’s Lab (Montreal, QC, Canada). He received his PhD degree in Linguistics from the Center for Language and Brain (HSE University, Moscow, Russia) in the field of language and communication in individuals with Autism Spectrum Disorder (ASD) and completed a postdoctoral training (2022–2025) in clinical electroencephalography at Seattle Children’s Research Institute, in Sara Jane Webb’s Lab (Seattle, WA, USA).

In his research, Dr. Vardan Arutiunian uses multiple approaches and methods, such as behavioral assessment, genetic approaches (polymorphism, genome-wide copy number variation), and neurobiological methods (e.g., magnetoencephalography, electroencephalography, brain morphometry) to investigate a variability of language skills as well as structural and functional brain mechanisms of language impairment in children with ASD.

Dr. Vardan Arutiunian’s current studies combine genetic, neuroimaging, and behavioral approaches to understand the biological basis of language in autistic individuals and their first-degree relatives. His studies also address the biomarkers of language impairments in ASD and the presence of these biomarkers in clinical trials. Furthermore, his research aims to identify the early neural markers of language impairments in infants at risk for developing ASD and to reveal the validity of these neural markers to predict long-term language outcome in children who will later be diagnosed with ASD.

Dr. Vardan Arutiunian received a number of research and teaching awards from several organizations in Russia, European Union, and the United States. He presented the main results of his studies in Russia, Germany, France, Italy, Singapore, Canada, United Arab Emirates, and the United States of America. Dr. Arutiunian, PhD, is a 2024 ARI Research Grantee.

The post Sustained Potential as a Biomarker of Language Functioning in Autism appeared first on Autism Research Institute.

More can be found here: Read More

ADHD self-advocate Natalie Gottret Murillo shares the lessons she has learned from living alone for the first time.

More can be found here: Read More

Free webinar at 1:00 p.m. Eastern time (US), April 1, 2026

Learn about evidence-based, effective nutritional strategies to manage constipation.

Managing Constipation

This field is for validation purposes and should be left unchanged.
Name(Required)



About the speaker:

Professional headshot of a person

Kelly Barnhill, MBA, CN, CCN, is the Director of the Nutrition Clinic at The Johnson Center for Child Health and Development. She is a Certified Clinical Nutritionist with over a decade of experience working with nutrition in children with autism and related disorders. At the Johnson Center, she directs a team of dieticians and nutritionists that has served over 3000 children through this practice.

In addition to her clinical practice, Kelly also serves as the Johnson Center Clinical Care Director, overseeing management and implementation of multidisciplinary care across the practices within the organization. In 2008, Kelly accepted the position of Nutrition Coordinator for the Autism Research Institute. In this role, she designs and manages curriculum and training for hundreds of nutrition practitioners each year, as well as providing direct training for thousands of parents. Kelly is a sought-after presenter, speaking at several national and international conferences each year.

Her studies and work at JCCHD are the culmination of many years’ effort and expertise, with the last several years devoted to understanding the biological underpinnings of the disorder we know as autism. Her work has raised awareness of the need for these services for children with autism and related disorders. Kelly is a graduate of the University of Texas at Austin.

Ms. Barnhill also sits on ARI’s Board of Directors and Scientific Advisory Board.

  • Biomarkers DNA image
2025-10-23T14:04:24-05:00

Towards the Development of a Diagnostic Test for Autism Spectrum Disorder: Data Science Meets Metabolomics

2025-10-23T14:04:24-05:00February 11th, 2026|Biomarkers, Genetics, Health, Immune Issues, Medical Care, Neurological, Research, Research, Webinar|

Free webinar at 1:00 p.m. Eastern time (US), February 11, 2026 Tune in to hear Juergen Hahn, M.S., Ph.D., ARI Scientific Advisory Board member, discuss how using machine learning can lead to biomarker

The post Managing Constipation appeared first on Autism Research Institute.

More can be found here: Read More

Diagnoses of Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD)

The post The Increase in Autism and ADHD Diagnoses: What’s Driving the Rise? appeared first on AngelSense.

This April, we celebrate Autism Acceptance Month to shine a

The post What Do the Autism Colors and Symbols Mean? appeared first on AngelSense.

Every year, when April rolls around, the goals of autism

The post Why Autism Acceptance Matters: Moving Beyond Awareness appeared first on AngelSense.

Having a child diagnosed with autism can bring about many

The post Helping Your Child with Autism Thrive appeared first on AngelSense.

Teaching emergency awareness to autistic children is a key part

The post Preparing Autistic Children for Emergencies: Safety Skills that Build Confidence appeared first on AngelSense.

Alex Alonso explores the benefits that following routines can have for neurodivergent individuals.

More can be found here: Read More

Special Time – Free webinar at 3:00 p.m. Eastern time (US), March 18, 2026

The IQSEC2 protein is a guanine nucleotide exchange factor for Arf6.  Pathogenic variants in the X-linked IQSEC2 gene are associated with drug-resistant epilepsy, severe intellectual disability, and autism.  The vast majority of disease-causing variants introduce premature termination codons in the IQSEC2 gene, resulting in little or no IQSEC2 protein being produced.   We sought to determine if an adeno-associated virus (AAV) containing the IQSEC2 gene could rescue abnormal phenotypes in mice in two different Iqsec2 mouse models with premature Iqsec2 termination codons resulting in a knockout of Iqsec2 gene expression and in mice with a A350V Iqsec2 missense mutation.  In Iqsec2 knockout mice, the AAV significantly improved growth, corrected behavioral abnormalities, and normalized the seizure threshold.  We propose that success in the Iqsec2 knockout mice warrants a proof-of-concept study for gene replacement therapy in boys with IQSEC2 premature termination variants.

This is a joint presentation with the World Autism Organization.

Gene Therapy for Mutations in the IQSEC2 Gene

This field is for validation purposes and should be left unchanged.
Name(Required)



About the speaker:

Prof. Andrew Levy received his BA Summa Cum Laude from Yale University in Molecular Biophysics and Biochemistry in 1982. He received a MSTP scholarship for his MD PHD training (1982-1990) at Johns Hopkins Medical School performing his PHD under Nobel Laureate Daniel Nathans working on the identification of a growth factor now known as Vascular Endothelial Growth Factor. He completed internal medicine residency at Johns Hopkins Hospital (1990-1992) and a cardiovascular fellowship at Brigham and Women’s Hospital at Harvard Medical School (1992-1996).  He is a tenured professor at Technion Faculty of Medicine, Technion Israel Institute of Technology in Haifa, Israel. His current focus of research is on developing treatments for IQSEC2 disease – a neurodevelopmental disorder associated with drug-resistant epilepsy, autism, and severe intellectual disability. Founder of IQSEC2 Research and Advocacy Foundation, a volunteer group of parents working towards providing support for parents, increasing awareness of IQSEC2.

  • Biomarkers DNA image
2025-10-23T14:04:24-05:00

Towards the Development of a Diagnostic Test for Autism Spectrum Disorder: Data Science Meets Metabolomics

2025-10-23T14:04:24-05:00February 11th, 2026|Biomarkers, Genetics, Health, Immune Issues, Medical Care, Neurological, Research, Research, Webinar|

Free webinar at 1:00 p.m. Eastern time (US), February 11, 2026 Tune in to hear Juergen Hahn, M.S., Ph.D., ARI Scientific Advisory Board member, discuss how using machine learning can lead to biomarker

The post Gene Therapy for Mutations in the IQSEC2 Gene appeared first on Autism Research Institute.

More can be found here: Read More